Abubacar, Pikaw L.
HRN: 14-63-73 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/28/2022
CEFTAZIDIME 1GM (VIAL)
07/28/2022
08/03/2022
IV
1g
Q8
DM Foot
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes